Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

By this fall, the FDA may approve a subcutaneous (SC) injection of the world’s top-selling cancer drug, pembrolizumab (Keytruda; Merck), that can be delivered to patients in 5 minutes or less. It is a change that Merck’s Marjorie Green, MD, senior vice president and head of oncology clinical development, predicts will “build on this breakthrough medicine to give patients and those who treat them better experiences.”¹